The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models
Abstract Reovirus type 3 Dearing (RT3D) is an oncolytic, double-stranded RNA virus. To identify potential RT3D drug-viral sensitizer, here we use a high-throughput screen of therapeutic agents and find a PARP-1 inhibitor, talazoparib, as a top hit. RT3D interacts with retinoic acid-induced gene-1 (R...
Saved in:
| Main Authors: | Joan Kyula-Currie, Victoria Roulstone, James Wright, Francesca Butera, Arnaud Legrand, Richard Elliott, Martin McLaughlin, Galabina Bozhanova, Dragomir Krastev, Stephen Pettitt, Tencho Tenev, Magnus Dillon, Shane Foo, Emmanuel C. Patin, Victoria Jennings, Charleen Chan Wah Hak, Elizabeth Appleton, Amarin Wongariyapak, Malin Pedersen, Antonio Rullan, Jyoti Choudhary, Chris Bakal, Pascal Meier, Christopher J. Lord, Alan Melcher, Kevin J. Harrington |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-025-61297-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion
by: Victoria Roulstone, et al.
Published: (2025-05-01) -
Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion
by: Victoria Roulstone, et al.
Published: (2025-07-01) -
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma
by: Victoria Jennings, et al.
Published: (2022-03-01) -
Mathematical modelling of reoviruses in cancer cell cultures.
by: Arwa Abdulla Baabdulla, et al.
Published: (2025-01-01) -
Cost-effectiveness of talazoparib plus enzalutamide as first-line therapy in metastatic castration-resistant prostate cancer
by: Jiaming Zhu, et al.
Published: (2025-08-01)